In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Lexicon Pharmaceuticals, Inc.. Trade Record

NASDAQ:LXRX Lexicon Pharmaceuticals, Inc. stock gains 116.36% Exit Sep 30, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart LXRX Sep 6, 2019, priceSeries
About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.96
Entry Date
Sep 6, 2019
Entry Price
1.38
Sell Date
Sep 30, 2019
Sell Price
2.99
Net Gain
116.36%
Hold Time
16 Trading Days